Skip to main content
Top
Published in: BMC Urology 1/2023

Open Access 01-12-2023 | Ureterectomy | Research

Segmental ureterectomy for high-risk ureteral carcinoma: a preliminary report

Authors: Wei Wei, Junfeng Liu, Lingdian Wang, Xiaoyu Duan, Degang Ding

Published in: BMC Urology | Issue 1/2023

Login to get access

Abstract

Background

EAU guidelines strongly recommend kidney sparing surgery (KSS) as the primary treatment option for the low-risk UTUC patients. While there are few reports involving the KSS treated for the high-risk counterparts, especially the ureteral resection.

Objective

To evaluate the effectiveness and safety of the segmental ureterectomy (SU) for the patients with high-risk ureteral carcinoma.

Materials and methods

We included 20 patients from May 2017 to December 2021 who underwent segmental ureterectomy (SU) in Henan Provincial People’s Hospital. The overall survival (OS) and progression free survival (PFS) were evaluated. Besides, the ECOG scores and postoperative complications were also included.

Results

As of December 2022, the mean OS was 62.1months (95%CI:55.6-68.6months) and the mean PFS was 45.0months (95%CI:35.9-54.1months). The median OS and median PFS were not reached. The 3-year OS rate was 70% and the 3-year PFS rate was 50%. The percentage of Clavien I and II complications was 15%.

Conclusion

For the selected patients with high-risk ureteral carcinoma, the efficacy and safety of segmental ureterectomy were satisfactory. But we still need to conduct prospective or randomized study to validate the value of SU in patients with high-risk ureteral carcinoma.
Literature
1.
go back to reference Siegel RL, Miller KD,Fuchs HE,Jemal A. Cancer statistics,2022.CA. Cancer J Clin. 2022;72(1):7–33.CrossRef Siegel RL, Miller KD,Fuchs HE,Jemal A. Cancer statistics,2022.CA. Cancer J Clin. 2022;72(1):7–33.CrossRef
2.
go back to reference Roupret M, Babjuk M, Burger M, Capoun O,Cohen, D,Compérat. EM,et al:European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2021;79(1):62–79.CrossRefPubMed Roupret M, Babjuk M, Burger M, Capoun O,Cohen, D,Compérat. EM,et al:European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2021;79(1):62–79.CrossRefPubMed
3.
go back to reference Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY,Babjuk. M,et al:oncologic outcomes of kidney-sparing surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a systematic review by the EAU non-muscle invasive bladder Cancer Guidelines Panel. Eur Urol. 2016;70(6):1052–68.CrossRefPubMed Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY,Babjuk. M,et al:oncologic outcomes of kidney-sparing surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a systematic review by the EAU non-muscle invasive bladder Cancer Guidelines Panel. Eur Urol. 2016;70(6):1052–68.CrossRefPubMed
4.
go back to reference Raman JD. Kidney sparing surgery for upper-tract urothelial carcinoma. Minerva Urol Nefrol. 2016;68(4):359–71.PubMed Raman JD. Kidney sparing surgery for upper-tract urothelial carcinoma. Minerva Urol Nefrol. 2016;68(4):359–71.PubMed
5.
go back to reference Collà Ruvolo C, Würnschimmel C, Wenzel M, Nocera L, Califano G, Tian Z, Shariat SF. Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. J Clin Pathol 2022 May;75(5):333–7. doi: https://doi.org/10.1136/jclinpath-2021-207400. Epub 2021 Feb 23. Collà Ruvolo C, Würnschimmel C, Wenzel M, Nocera L, Califano G, Tian Z, Shariat SF. Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. J Clin Pathol 2022 May;75(5):333–7. doi: https://​doi.​org/​10.​1136/​jclinpath-2021-207400. Epub 2021 Feb 23.
6.
go back to reference Collà Ruvolo C, Deuker M, Wenzel M, Nocera L, Würnschimmel C, Califano G et al. Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinoma. Urol Oncol. 2022 Sep;40(9): 411.e1-411.e8. doi: https://doi.org/10.1016/j.urolonc.2022.06.009. Epub 2022 Jul 25. Collà Ruvolo C, Deuker M, Wenzel M, Nocera L, Würnschimmel C, Califano G et al. Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinoma. Urol Oncol. 2022 Sep;40(9): 411.e1-411.e8. doi: https://​doi.​org/​10.​1016/​j.​urolonc.​2022.​06.​009. Epub 2022 Jul 25.
7.
go back to reference Momota M, Hatakeyama S, Tokui N, Sato T,Yamamoto H,Tobisawa. Y,et al:the impact of preoperative severe renal insufficiency on poor postsurgical oncological prognosis in patients with urothelial carcinoma. Eur Urol Focus. 2019;5(6):1066–73.CrossRefPubMed Momota M, Hatakeyama S, Tokui N, Sato T,Yamamoto H,Tobisawa. Y,et al:the impact of preoperative severe renal insufficiency on poor postsurgical oncological prognosis in patients with urothelial carcinoma. Eur Urol Focus. 2019;5(6):1066–73.CrossRefPubMed
8.
go back to reference Birtle A, Johnson M, Chester J, Jones, R,Dolling D,Bryan. RT,et al:adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label. randomised controlled trial Lancet. 2020;395(10232):1268–77.PubMed Birtle A, Johnson M, Chester J, Jones, R,Dolling D,Bryan. RT,et al:adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label. randomised controlled trial Lancet. 2020;395(10232):1268–77.PubMed
9.
go back to reference Coleman JA. Yip W,Wong NC,Sjoberg DD,Bochner BH,Dalbagni G,:Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients with High-Grade Upper Tract Urothelial Carcinoma.J Clin Oncol.2023; JCO2200763. Coleman JA. Yip W,Wong NC,Sjoberg DD,Bochner BH,Dalbagni G,:Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients with High-Grade Upper Tract Urothelial Carcinoma.J Clin Oncol.2023; JCO2200763.
10.
go back to reference Xylinas E, Rink M, Margulis V, Clozel T, Lee RK,Comploj. E,et al:impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. Bju Int. 2013;112(4):453–61.CrossRefPubMed Xylinas E, Rink M, Margulis V, Clozel T, Lee RK,Comploj. E,et al:impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. Bju Int. 2013;112(4):453–61.CrossRefPubMed
11.
go back to reference Fang D, Seisen T, Yang K,Liu P,Fan X,Singla. N,et al:a systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma. Ejso-Eur J Sug Onc. 2016;42(11):1625–35.CrossRef Fang D, Seisen T, Yang K,Liu P,Fan X,Singla. N,et al:a systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma. Ejso-Eur J Sug Onc. 2016;42(11):1625–35.CrossRef
12.
go back to reference Hendriks N, Baard J, Beerlage HP,Schout BMA. Doherty KSG,Pelger RCM,et al:Survival and Long-term Effects of kidney-sparing surgery Versus Radical Nephroureterectomy on kidney function in patients with Upper urinary tract Urothelial Carcinoma. Eur Urol Open Sci. 2022;40:104–11.CrossRefPubMedPubMedCentral Hendriks N, Baard J, Beerlage HP,Schout BMA. Doherty KSG,Pelger RCM,et al:Survival and Long-term Effects of kidney-sparing surgery Versus Radical Nephroureterectomy on kidney function in patients with Upper urinary tract Urothelial Carcinoma. Eur Urol Open Sci. 2022;40:104–11.CrossRefPubMedPubMedCentral
13.
go back to reference Shen CY. Jou YC,Kan WC,Tzai TS,Tsai YS:Outcome of Non-Muscle Invasive Upper Tract Urothelial Carcinoma Receiving Endoscopic Ablation: An Inverse Probability of Treatment Weighting Analysis.J Clin Med.2022;11(5) Shen CY. Jou YC,Kan WC,Tzai TS,Tsai YS:Outcome of Non-Muscle Invasive Upper Tract Urothelial Carcinoma Receiving Endoscopic Ablation: An Inverse Probability of Treatment Weighting Analysis.J Clin Med.2022;11(5)
14.
go back to reference Collà Ruvolo C, Nocera L, Stolzenbach LF, Wenzel M, Califano G, Tian Z, et al. Tumor size predicts muscle-invasive and non-organ-confined disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. Eur Urol Focus. 2022 Mar;8(2):498–505. Collà Ruvolo C, Nocera L, Stolzenbach LF, Wenzel M, Califano G, Tian Z, et al. Tumor size predicts muscle-invasive and non-organ-confined disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. Eur Urol Focus. 2022 Mar;8(2):498–505.
15.
go back to reference Foerster B, Abufaraj M, Matin SF,Azizi M,Gupta M, Li. WM,et al:pretreatment risk stratification for endoscopic kidney-sparing surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. Eur Urol. 2021;80(4):507–15.CrossRefPubMed Foerster B, Abufaraj M, Matin SF,Azizi M,Gupta M, Li. WM,et al:pretreatment risk stratification for endoscopic kidney-sparing surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. Eur Urol. 2021;80(4):507–15.CrossRefPubMed
16.
go back to reference Shishido SN, Ghoreifi A, Sayeed S, Courcoubetis G,Huang A,Ye B et al. Liquid Biopsy Landscape in Patients with Primary Upper Tract Urothelial Carcinoma.Cancers (Basel).2022;14(12). Shishido SN, Ghoreifi A, Sayeed S, Courcoubetis G,Huang A,Ye B et al. Liquid Biopsy Landscape in Patients with Primary Upper Tract Urothelial Carcinoma.Cancers (Basel).2022;14(12).
17.
go back to reference Seisen T, Nison L,Remzi M, Klatte T, Mathieu R,Lucca. I,et al:oncological outcomes of radical nephroureterectomy versus kidney-sparing surgery for elective treatment of clinically organ-confined upper tract urothelial carcinoma of the distal ureter. J Urol. 2016;195(5):1354–61.CrossRefPubMed Seisen T, Nison L,Remzi M, Klatte T, Mathieu R,Lucca. I,et al:oncological outcomes of radical nephroureterectomy versus kidney-sparing surgery for elective treatment of clinically organ-confined upper tract urothelial carcinoma of the distal ureter. J Urol. 2016;195(5):1354–61.CrossRefPubMed
19.
go back to reference Panos G, Mulita F, Akinosoglou K, Liolis E, Kaplanis C, Tchabashvili L et al. Risk of surgical site infections after colorectal surgery and the most frequent pathogens isolated: a prospective single-centre observational study. Med Glas (Zenica). 2021 Aug 1;18(2):438–443. Panos G, Mulita F, Akinosoglou K, Liolis E, Kaplanis C, Tchabashvili L et al. Risk of surgical site infections after colorectal surgery and the most frequent pathogens isolated: a prospective single-centre observational study. Med Glas (Zenica). 2021 Aug 1;18(2):438–443.
20.
go back to reference Mulita F, Liolis E, Akinosoglou K, Tchabashvili L, Maroulis I, Kaplanis C, et al. Postoperative sepsis after colorectal surgery: a prospective single-center observational study and review of the literature. Prz Gastroenterol. 2022;17(1):47–51.PubMed Mulita F, Liolis E, Akinosoglou K, Tchabashvili L, Maroulis I, Kaplanis C, et al. Postoperative sepsis after colorectal surgery: a prospective single-center observational study and review of the literature. Prz Gastroenterol. 2022;17(1):47–51.PubMed
21.
go back to reference Masson-Lecomte A, Vaillant V,Roumiguié M,Lévy, S,Pradère B,Peyromaure. M,:Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee.Cancers (Basel).2022;14(21). Masson-Lecomte A, Vaillant V,Roumiguié M,Lévy, S,Pradère B,Peyromaure. M,:Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee.Cancers (Basel).2022;14(21).
Metadata
Title
Segmental ureterectomy for high-risk ureteral carcinoma: a preliminary report
Authors
Wei Wei
Junfeng Liu
Lingdian Wang
Xiaoyu Duan
Degang Ding
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Ureterectomy
Published in
BMC Urology / Issue 1/2023
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-023-01265-y

Other articles of this Issue 1/2023

BMC Urology 1/2023 Go to the issue